Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune checkpoint inhibitor (ICI) monotherapy can prolong overall survival compared with patients receiving single-agent c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-10-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605211042988 |